Polymorphisms in interleukin 1 beta and interleukin 1 receptor antagonist associated with tumor recurrence in stage II colon cancer

Purpose Identifying molecular markers for tumor recurrence is critical in successfully selecting patients with stage II colon cancer who are more likely to benefit from adjuvant chemotherapy. Interleukin 1 beta (IL1B) and interleukin 1 receptor antagonist (IL1RN) have been shown to play a critical role in the early onset of tumor-associated angiogenesis. In this study, we tested whether eight functionally significant polymorphisms within six genes of the angiogenesis pathway [IL1B, IL1RN, vascular endothelial growth factor A (VEGFA), VEGF receptor 2, interleukin-8, cyclooxygenase-2] will predict the risk of tumor recurrence in stage II colon cancer patients treated with 5-fluorouracil based adjuvant chemotherapy. Experimental design Blood samples were obtained from 109 patients with stage II colon cancer at the University of Southern California medical facilities. DNA was extracted from peripheral blood and the genotypes were analyzed using PCR-restriction fragment length polymorphism protocols. Results Patients harboring the IL1RN/IL1B 1-T-C (IL-1RN variable number tandem repeats (VNTR)/IL1B C+3954T/C-511T) haplotype were at greatest risk of developing tumor recurrence [relative risk (RR): 2.72, 95% confidence interval (CI): 1.22–6.08] (adjusted P=0.015). In addition, IL1B +3954 any T (RR: 2.78, 95% CI: 0.99–7.83) (adjusted P=0.043), IL1RN VNTR (RR: 6.09, 95% CI: 1.11–33.4) (adjusted P=0.038), and VEGFA –634 any C (RR: 2.91, 95% CI: 1.13–7.48) (adjusted P=0.026) were shown to be adverse prognostic markers, in both univariate and multivariable analyses. Conclusion Polymorphisms in IL1B, IL1RN, and VEGFA as well as IL1B/IL1RN haplotype analysis may serve as molecular markers for tumor recurrence in stage II colon cancer, indicating that the analysis of angiogenesis-related gene polymorphisms may help to identify patient subgroups at high risk for tumor recurrence.

[1]  F. Pociot,et al.  A Taql polymorphism in the human interleukin‐1β (IL‐1β) gene correlates with IL‐1β secretion in vitro , 1992 .

[2]  F. Pociot,et al.  A TaqI polymorphism in the human interleukin-1 beta (IL-1 beta) gene correlates with IL-1 beta secretion in vitro. , 1992, European journal of clinical investigation.

[3]  J. Folkman.  Angiogenesis in cancer, vascular, rheumatoid and other disease , 1995, Nature Medicine.

[4]  M. Neeman,et al.  Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids: implications for tumor angiogenesis. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[5]  M. Goldberg,et al.  Transcriptional Regulation of the Rat Vascular Endothelial Growth Factor Gene by Hypoxia (*) , 1995, The Journal of Biological Chemistry.

[6]  D. Grennan,et al.  Cytokine production by normal human monocytes: inter‐subject variation and relationship to an IL‐1 receptor antagonist (IL‐1Ra) gene polymorphism , 1995, Clinical and experimental immunology.

[7]  O. Dent,et al.  Survival after curative resection of lymph node negative colorectal carcinoma , 1995, Cancer.

[8]  C. Tangen,et al.  Fluorouracil plus Levamisole as Effective Adjuvant Therapy after Resection of Stage III Colon Carcinoma: A Final Report , 1995, Annals of Internal Medicine.

[9]  M. Goldberg,et al.  Post-transcriptional Regulation of Vascular Endothelial Growth Factor by Hypoxia (*) , 1996, The Journal of Biological Chemistry.

[10]  L. Ellis,et al.  Platelet-derived endothelial cell growth factor in human colon cancer angiogenesis: role of infiltrating cells. , 1996, Journal of the National Cancer Institute.

[11]  C. Dinarello,et al.  Biologic basis for interleukin-1 in disease. , 1996, Blood.

[12]  L. Ellis,et al.  Vessel counts and expression of vascular endothelial growth factor as prognostic factors in node-negative colon cancer. , 1997, Archives of surgery.

[13]  D. Obrand,et al.  Incidence and patterns of recurrence following curative resection for colorectal carcinoma , 1997, Diseases of the colon and rectum.

[14]  F. Bosman,et al.  For patients with dukes' B (TNM stage II) colorectal carcinoma, examination of six or fewer lymph nodes is Related to poor prognosis , 1998, Cancer.

[15]  L. Ellis,et al.  Regulation of vascular endothelial growth factor expression in human colon cancer by interleukin-1β , 1999, British Journal of Cancer.

[16]  E. Oevermann,et al.  Ordinary colorectal adenocarcinoma vs. primary colorectal signet-ring cell carcinoma: study matched for age, gender, grade, and stage. , 1999, Diseases of the colon and rectum.

[17]  E. Oevermann,et al.  Ordinary colorectal adenocarcinomavs. primary colorectal signet-ring cell carcinoma , 1999 .

[18]  M. Bottomley,et al.  Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. , 2000, Cytokine.

[19]  M. Fey.  [Adjuvant therapy for colon cancer]. , 2000, Schweizerische medizinische Wochenschrift.

[20]  W. Renner,et al.  A Common 936 C/T Mutation in the Gene for Vascular Endothelial Growth Factor Is Associated with Vascular Endothelial Growth Factor Plasma Levels , 2000, Journal of Vascular Research.

[21]  M. Carrington,et al.  Interleukin-1 polymorphisms associated with increased risk of gastric cancer , 2000, Nature.

[22]  W. Hohenberger,et al.  High‐risk groups of patients with Stage II colon carcinoma , 2001, Cancer.

[23]  P J Catalano,et al.  Molecular predictors of survival after adjuvant chemotherapy for colon cancer. , 2001, The New England journal of medicine.

[24]  D. Hinton,et al.  Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor-positive human tumors. , 2001, Blood.

[25]  H. Dvorak.  Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Ikuo Inoue,et al.  A common polymorphism in the 5'-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes. , 2002, Diabetes.

[27]  Yun-Jin Jung,et al.  IL-1beta-mediated up-regulation of HIF-1alpha via an NFkappaB/COX-2 pathway identifies HIF-1 as a critical link between inflammation and oncogenesis. , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[28]  L. Ellis,et al.  Cyclooxygenase-2 is up-regulated by interleukin-1 beta in human colorectal cancer cells via multiple signaling pathways. , 2003, Cancer research.

[29]  C. Compton.  Colorectal Carcinoma: Diagnostic, Prognostic, and Molecular Features , 2003, Modern Pathology.

[30]  Y. Kodera,et al.  Survival After Curative Resection for Mucinous Adenocarcinoma of the Colorectum , 2003, Diseases of the colon and rectum.

[31]  L. Neckers,et al.  IL‐1β mediated up‐regulation of HIF‐lα via an NFkB/COX‐2 pathway identifies HIF‐1 as a critical link between inflammation and oncogenesis , 2003 .

[32]  Y. Iwakura,et al.  IL-1 is required for tumor invasiveness and angiogenesis , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[33]  C. Nelson,et al.  The p38 mitogen‐activated protein kinase regulates interleukin‐1β‐induced IL‐8 expression via an effect on the IL‐8 promoter in intestinal epithelial cells , 2003, Immunology.

[34]  L. Ellis,et al.  Interleukin-1beta regulates angiopoietin-1 expression in human endothelial cells. , 2004, Cancer research.

[35]  R. Bendardaf,et al.  Prognostic and predictive molecular markers in colorectal carcinoma. , 2004, Anticancer research.

[36]  L. Ellis,et al.  Role of hypoxia-inducible factor 1alpha in gastric cancer cell growth, angiogenesis, and vessel maturation. , 2004, Journal of the National Cancer Institute.

[37]  E. Maltezos,et al.  VEGF gene sequence variation defines VEGF gene expression status and angiogenic activity in non-small cell lung cancer. , 2004, Lung cancer.

[38]  L. Ellis,et al.  Interleukin-1β Regulates Angiopoietin-1 Expression in Human Endothelial Cells , 2004 .

[39]  D. Phillips,et al.  Interleukin 1 receptor antagonist gene polymorphism and risk of lung cancer: a possible interaction with polymorphisms in the interleukin 1 beta gene. , 2005, Lung cancer.

[40]  V. Catalano,et al.  Interleukin 1B gene (IL-1B) and interleukin 1 receptor antagonist gene (IL-1RN) polymorphisms in Helicobacter pylori-negative gastric cancer of intestinal and diffuse histotype. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[41]  G. Matullo,et al.  Interleukin-1 Gene Polymorphisms and Gastric Cancer Risk in a High-Risk Italian Population , 2005, The American Journal of Gastroenterology.

[42]  K. Hemminki,et al.  Vascular Endothelial Growth Factor Polymorphisms in Relation to Breast Cancer Development and Prognosis , 2005, Clinical Cancer Research.

[43]  L. Ellis,et al.  Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  Toshihiro Tanaka,et al.  Combined Effect of 25-Hydroxycholesterol and IL-1β on IL-8 Production in Human Colon Carcinoma Cell Line (Caco-2) , 2006, Inflammation.

[45]  E. Fontham,et al.  Interleukin-1beta and interleukin-1 receptor antagonist gene polymorphisms and gastric cancer: a meta-analysis. , 2006, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[46]  C. Tournigand,et al.  Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  E. Fontham,et al.  Interleukin-1β and Interleukin-1 Receptor Antagonist Gene Polymorphisms and Gastric Cancer: A Meta-analysis , 2006, Cancer Epidemiology Biomarkers & Prevention.

[48]  H. Lenz,et al.  Molecular prognostic markers in locally advanced colon cancer. , 2007, Clinical colorectal cancer.

[49]  S. Groshen,et al.  Polymorphisms in VEGF and IL-8 predict tumor recurrence in stage III colon cancer. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[50]  J. Park,et al.  Vascular Endothelial Growth Factor Gene Polymorphisms Associated with Prognosis for Patients with Colorectal Cancer , 2008, Clinical Cancer Research.

[51]  A. Jemal,et al.  Cancer Statistics, 2008 , 2008, CA: a cancer journal for clinicians.